X
    學術可視化工作室RC   登錄   提交文稿
學術英文編修

ATHEROSCLEROSIS

期刊標題檢索 ATHEROSCLEROSIS 最新評論: Do we need to laminate this magazine? (2024-05-07)


期刊名稱:   ISSN:   主題領域:   影響因子範圍: -
索引:   類別:   開放訪問:   排序方式:

[ATHEROSCLEROSIS]您好,您是該頁面的第 77359 位訪客。

期刊簡介
期刊名稱ATHEROSCLEROSIS ATHEROSCLEROSIS
LetPub Score
7.7
50 ratings
Rate

Reputation
8.8

Influence
6.6

Speed
9.1

期刊簡稱ATHEROSCLEROSIS
ISSN0021-9150
E-ISSN1879-1484
h-index159
CiteScore
CiteScoreSJRSNIPCiteScore Rank
9.801.4611.203
Subject fieldQuartilesRankPercentile
Category: Medicine
Subcategory: Cardiology and Cardiovascular Medicine
Q145 / 387

自引率 (2023-2024)4.10%自引率趨勢
掲載範囲
Atherosclerosis has an open access mirror journal Atherosclerosis: X, sharing the same aims and scope, editorial team, submission system and rigorous peer review.

Atherosclerosis brings together, from all sources, papers concerned with investigation on atherosclerosis, its risk factors and clinical manifestations. Atherosclerosis covers basic and translational, clinical and population research approaches to arterial and vascular biology and disease, as well as their risk factors including: disturbances of lipid and lipoprotein metabolism, diabetes and hypertension, thrombosis, and inflammation. The Editors are interested in original or review papers dealing with the pathogenesis, environmental, genetic and epigenetic basis, diagnosis or treatment of atherosclerosis and related diseases as well as their risk factors.
官方網站http://www.journals.elsevier.com/atherosclerosis/
在線稿件提交https://www.editorialmanager.com/ATH
開放訪問No
出版商Elsevier Ireland Ltd
主題領域医学
出版國/地區UNITED STATES
發行頻率月刊
創刊年1970
每年文章數193每年文章數趨勢
黃金OA百分比34.14%
Web of Science 四分位
2023-2024
WOS Quartile: Q1

CategoryEditionJIF QuartileJIF RankingJIF Percentage
CARDIAC & CARDIOVASCULAR SYSTEMSSCIEQ140/220
PERIPHERAL VASCULAR DISEASESCIEQ114/96
索引 (SCI or SCIE)Science Citation Index
Science Citation Index Expanded
鏈接到PubMed Central (PMC)https://www.ncbi.nlm.nih.gov/nlmcatalog?term=0021-9150%5BISSN%5D
平均審稿時間 *來自出版商的數據:
來自作者的數據: Average 3 Month(s)
來自Elsevier的數據: Average 7.7 Week(s)
競爭力 *來自作者的數據: About 33.33%
來自Elsevier的數據: 32%
在線文章發布時間來自Elsevier的數據: Average 4.7 Week(s)
參考鏈接
相關期刊 【ATHEROSCLEROSIS】CiteScore趨勢
自引率趨勢 每年文章數趨勢
作者評論
*所有的審稿過程指標,如接受率和審稿速度,僅限於用戶提交的稿件。因此,這些指標可能無法準確反映期刊的競爭力或速度。
  • 同一學科的期刊
  • CiteScore趨勢
  • 自引率趨勢
  • 每年文章數趨勢
  •  
    學科內的可信期刊 影響因子
    CIRCULATIONH-index: 570

    CiteScore: 45.70
    CIRCULATION RESEARCHH-index: 306

    CiteScore: 29.60
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGYH-index: 251

    CiteScore: 15.60
    HYPERTENSIONH-index: 246

    CiteScore: 15.90
    International Journal of StrokeH-index: 59

    CiteScore: 13.90
    JOURNAL OF THROMBOSIS AND HAEMOSTASISH-index: 154

    CiteScore: 24.30
    THROMBOSIS AND HAEMOSTASISH-index: 178

    CiteScore: 11.90
    HYPERTENSION RESEARCHH-index: 78

    CiteScore: 7.40
    CURRENT HYPERTENSION REPORTSH-index: 63

    CiteScore: 10.50
    THROMBOSIS RESEARCHH-index: 102

    CiteScore: 14.60
    學科內最受檢索的期刊 頁面查看次數
    CIRCULATION118395
    CIRCULATION RESEARCH93058
    HYPERTENSION80393
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY66680
    JOURNAL OF HYPERTENSION51801
    THROMBOSIS RESEARCH43903
    HYPERTENSION RESEARCH42844
    THROMBOSIS AND HAEMOSTASIS38864
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS35811
    International Journal of Stroke35385
  •  

    ATHEROSCLEROSIS ATHEROSCLEROSIS
    明年預測:
    穩步上升 無變化 逐步下降  刷新
  •  

     
  •  

     


首頁    上一頁    1    2    3    下一頁    末頁  (頁
/3)
  [ATHEROSCLEROSIS] 的評論撰寫評論
作者: 震雷宛畅


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2024-05-07 16:09:51 評論於
Do we need to laminate this magazine?
(0) 讚! | 震雷宛畅

作者: 含莲酱吖


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-06-18 09:06:19 評論於
Review Speed: 6.0 | Submission Acceptance Rate: 50.0
Experience Sharing: 1
(0) 讚! | 含莲酱吖

作者: 伯吉斯尤利西斯


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-03-31 20:11:32 評論於
It has been a week since the revised manuscript was sent back. Is there still hope for a decision in process?
(0) 讚! | 伯吉斯尤利西斯

作者: 惜芹可爱吗


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-03-21 19:06:22 評論於
You
(0) 讚! | 惜芹可爱吗

作者: 惜芹可爱吗


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-03-21 17:03:03 評論於
Is this magazine open to having co-corresponding authors (two correspondents)?
(0) 讚! | 惜芹可爱吗

作者: 努力啊大巧莲


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-03-01 09:42:04 評論於
Normally, it takes a long time to receive feedback even when returning to editing. Last year, I waited a month at the "decision in process" step when I submitted
(0) 讚! | 努力啊大巧莲

作者: 风啸诗霜


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2023-02-15 20:21:14 評論於
All review completed for nearly a month now, is this normal? The reviewers have all finished their evaluations, but I still haven't received any feedback. I'm getting anxious
(0) 讚! | 风啸诗霜

作者: 碧桃含文


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-12-16 16:56:44 評論於
Received at Editorial Office: 5 May 2022
Article revised: 12 Nov 2022
Article accepted for publication: 13 Dec 2022
(0) 讚! | 碧桃含文

作者: 碧桃含文


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-12-16 13:52:02 評論於
Review Speed: 1.0
Experience Sharing: Received at Editorial Office 5 May 2022
Article revised 12 Nov 2022
Article accepted for publication 13 Dec 2022
(0) 讚! | 碧桃含文

作者: 碧桃含文


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-12-11 18:46:41 評論於
Western holidays are coming
(0) 讚! | 碧桃含文

作者: 珉林恨桃


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-11-13 15:52:34 評論於
Research focus: Atherosclerosis; Cardiovascular; Clinical epidemiology
Experience sharing: Been under review for almost two months and only received one acceptance invitation... Is everyone else this slow too?
(0) 讚! | 珉林恨桃

作者: 碧桃含文


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-10-04 17:01:38 評論於
That means it has not been submitted for external review yet
(0) 讚! | 碧桃含文

作者: 努力啊大巧莲


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-09-27 17:32:28 評論於
There is a link in the corresponding author's email
(0) 讚! | 努力啊大巧莲

作者: 珉林恨桃


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-09-26 10:00:27 評論於
I didn't see the tracking link after being under re
(0) 讚! | 珉林恨桃

作者: 努力啊大巧莲


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-08-23 16:06:22 評論於
Decision in process. Rejection after one month. A very long rejection letter, I can see that the reviewers are definitely industry experts, and their comments are very insightful. Will submit to another journal
(0) 讚! | 努力啊大巧莲

作者: 碧桃含文


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-08-11 14:58:25 評論於
Around 6:20
(0) 讚! | 碧桃含文

作者: 努力啊大巧莲


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-08-09 20:22:52 評論於
What day did you make this decision? Was it also in July?
(0) 讚! | 努力啊大巧莲

作者: 碧桃含文


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-08-08 15:26:50 評論於
There was no rush, so I made my decision in a week
(0) 讚! | 碧桃含文

作者: 努力啊大巧莲


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-08-03 22:40:59 評論於
OP, have you sent any emails to urge progress midway? I have been in the decision process for 2 weeks, not sure if it's appropriate to ask. Seeking advice
(0) 讚! | 努力啊大巧莲

作者: 碧桃含文


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-07-31 20:50:03 評論於
Please translate the following paragraph into English and Japanese, with titles ":" and ":"
(0) 讚! | 碧桃含文

作者: 碧桃含文


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-07-27 20:15:59 評論於
Let's cheer each other on
(0) 讚! | 碧桃含文

作者: 努力啊大巧莲


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-07-27 10:30:54 評論於
Decision in process for a whole week now, the review process seems to be slowing down recently, as Europe is on summer holiday and the editors are mostly university professors. Feeling restless
(0) 讚! | 努力啊大巧莲

作者: 碧桃含文


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-07-27 08:47:58 評論於
What did the original poster say? What was the final result?
(0) 讚! | 碧桃含文

作者: 努力啊大巧莲


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-07-19 13:44:28 評論於
OP is excellent. Keep it up
(0) 讚! | 努力啊大巧莲

作者: 努力啊大巧莲


領域: 医学
審稿時間: 0.0 month(s)
結果: 待定&不明


撰寫評論

2022-07-12 18:14:41 評論於
Review speed: 1.0 | Submission acceptance rate: 25.0
Experience sharing: The experiment design is relatively simple, and the supervisor requested that it must be submitted to AS. I also know that the likelihood of rejection is high. I will first provide some data on the submission time. Submitted to Editor assigned took about 3 days, with the editor status lasting about 4 days. After updating the date once midway, it quickly entered the "Under review" stage. I saw 2+ reviewer invitations sent out in the Tracking link, with initially only 1 agreeing to review. Initially thinking it was only 1 reviewer, I was happy, but in the end, it was 2+. It has been exactly 1 month since submission, with all reviews completed, and now in the "Decision in process" stage. I am preparing for the next journal. I hope the supervisor can achieve his dream through his next student
(0) 讚! | 努力啊大巧莲

首頁    上一頁    1    2    3    下一頁    末頁  (頁
/3)

開始撰寫 [ATHEROSCLEROSIS] 的評論:





Contact us

Contact us  

Your name*

Your email*

Your message*

Please fill in all fields and provide a valid email.

Security Code*